All In Biotech

Drug Trial Radar · NCT07278362

Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance

Safety of Intramuscular Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

35

Planned (sponsor's estimate)

Start

Nov 30, 2026

Primary completion

May 31, 2031

Study completion May 31, 2032

Sponsor

Lead sponsor
University of MiamiAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is evaluate the safety of testosterone replacement therapy in men with newly diagnosed low-risk prostate cancer and hypogonadism on active surveillance.

Conditions

  • Prostate Cancer
  • Hypogonadism, Male

Interventions

  • Testosterone cypionateDrug

    Participants will self-inject 100mg of testosterone cypionate once per week for 12 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants with Disease Progression Within 12 Months After Initiating TRTTime frame: 12 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Desai Sethi Urology Institute

    Miami, Florida · Recruiting

  • Sylvester Comprehensive Cancer Center

    Miami, Florida · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.